Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3801 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Sanofi drug should be limited, says panel

The FDA has recommended the drug’s continued use for community acquired pneumonia, although only as a secondary treatment. The FDA committee concluded that the risks outweigh the benefits

Tibotec breakthrough HIV therapy recommended

Tibotec said it anticipates receiving the conditional marketing authorization from the European Commission by early next year. The positive opinion is based on the efficacy and safety results

J&J submits antibiotic to FDA

Doripenem belongs to a class of antibacterial agents called carbapenems, which are useful in treating life-threatening infections caused by gram-positive and resistant gram-negative bacteria. Pseudomonas, a gram-negative bacterium,

Advancis applies for Amoxicillin approval

Amoxicillin Pulsys has previously faced setbacks when the drug failed clinical trials. However a recent phase III trial of Amoxicillin Pulsys successfully met its primary and secondary endpoints.

GSK vaccine gets EU endorsement

Daronrix is intended for the prevention of influenza during a pandemic situation, once the pandemic viral strain has been included. The mock-up pandemic influenza vaccine is not expected